SHINE Medical Technologies has closed an $80 million Series C financing round, the company announced recently.

“This funding round will help SHINE’s continuing efforts to commercialize vital diagnostic and therapeutic isotopes that will be created by our revolutionary, responsible production technologies,” SHINE CEO Greg Piefer said in a statement.

According to a release, Fidelity Management and Research Company led the round, which also included participation from other new investors and the company’s current investors.

In May, SHINE announced that the U.S. Nuclear Regulatory Commission expects to make a final determination regarding the issuance of an operating license by October 2021.